Dementia Support Line
Our comment about NICE reviewing the case for lecanemab and donanemab
Alzheimer's Society welcomes the decision and says the Government must be ambitious about preparing for new treatments.
Michelle Dyson CB, Chief Executive Officer at Alzheimer’s Society, said:
'We welcome NICE's decision to look again at the case for lecanemab and donanemab, particularly at the significant impact of dementia on unpaid carers. We know that carers are too often pushed to breaking point and this needs to be properly recognised.
People living with dementia are desperate for new treatments that delay the progression of symptoms and help them stay independent for longer.
'The science is moving fast and globally more people are starting to access these drugs, but the UK is falling behind. With over 30 Alzheimer’s disease drugs in late-stage clinical trials, there are likely to be more treatments submitted for approval soon.
'The Government must be ambitious about preparing for new treatments in their upcoming dementia plan. Time is ticking and it’s important that people with dementia in the UK don’t miss out.'
Researching new drugs for Alzheimer’s disease
Explore the next wave of promising new drugs.
